AST News Update Archives

The CLSI AST Outreach Working Group (ORWG) is part of the CLSI Subcommittee on Antimicrobial Susceptibility Testing (AST) and was established in 2015. The formation of the working group originated in a desire to efficiently convey information regarding contemporary AST practices, recommendations, and resources to the clinical microbiology community.

Sign-up For the AST News Update Emails

Archived News Updates:

• Volume 9, Issue 1 - January 2024 (English)
  • M100 Update: Practical Tips for Using Newly Formatted Tables 1 in CLSI M100 33rd Edition
    
  • AST Article: Acinetobacter – the Bad, the Awful, and the Downright Ugly
  • AST Article: Sulbactam-Durlobactam: The “double beta-lactamase inhibitor” drug
  • Case Study: Antifungal Body Site Reporting for Candida spp.

• Volume 8, Issue 1 - June 2023 (English)
  • M100 Update: New! CLSI M100-Ed33: Updated Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas aeruginosa
    
  • AST Article: New CLSI Intrinsic Resistance Guidance for Fungi
  • AST Article: The Latest on Testing Cefiderocol
  • Case Study: Aminoglycoside Case Study

• Volume 7, Issue 1 - June 2022 (Chinese)
  • 专题文章： 阳性血培养物直接纸片扩散法
  • 病例分析:这张图片有什么问题吗?
    • 凝固酶阴性葡萄球菌
    • 粘质沙雷菌
  • 实用技巧: 折点更新
  • 热点: 耳念珠菌和两性霉素B
  • 更多新闻!
    
    • ASM更新IQCP指南
    • 加入CLSI-EUCAST工作组
  • 纪念: James A. Poupard博士 (1943-2022)

• Volume 7, Issue 1 - June 2022 (English)
  • Featured Article: Direct Disk Diffusion Testing From Positive Blood Cultures
  • Case Studies: What’s Wrong with This Picture?
    • Coagulase-negative Staphylococcus spp.
    • Serratia marcescens
  • Practical Tips: Updating Breakpoints
  • Hot Topic: Candida auris and Amphotericin B
  • More News!
    • ASM Updates IQCP Guidance
    • Joint CLSI-EUCAST Working Group
  • In Memoriam: James A. Poupard, PhD (1943-2022)

• Volume 6, Issue 1 - April 2021 (Español)
  Translation by:
  Elizabeth Palavecino, MD, Director of Clinical Microbiology, Wake Forest Baptist Medical Center
  Translation proofing by:
  German Esparza, MSc, Director of Clinical Micro Proficiency Testing Proasecal, Proasecal LTD and Maria Jose Machado, MSc,CLSSGB, Microbiologist-Goldbelt C6, LLC, Centers for Disease Control and Prevention
  • Artículo destacado: Re-explorar la categoría interpretativa intermedia
  • Caso práctico: Valor de Intermedio ^ o “I^"
  • Consejos prácticos: ¿Qué hay de malo con esta imagen?
  • Tema de actualidad: Imipenem-Relebactam y AztreonamAvibactam: ¿Qué necesitan saber los microbiólogos clínicos y de salud pública?
  • ¡Más noticias! M100 En China

• Volume 6, Issue 1 - April 2021 (Chinese)
  • 专题文章： 对中介解释分类的再探讨
  • 病例分析： 中介^ 或 “I^” 的价值
  • 实用技巧： 此情此景有什么问题?
  • 热门话题： 亚胺培南-瑞来巴坦和氨曲南-阿维巴坦：临床 和公共卫生微生物学同道需要知道什么?
  • 更多新闻！ CLSI M100 在中国

• Volume 6, Issue 1 - April 2021 (English)
  • Feature Article: Re-Exploring the Intermediate Interpretive Category
  • Case Study: Value of Intermediate^ or “I^”
  • Practical Tips: What’s Wrong With This Picture
  • Hot Topic: Imipenem-Relebactam and Aztreonam- Avibactam: What Do Clinical and Public Health Microbiologists Need to Know?
  • More News!: M100 in China

• Volume 5, Issue 2 - July 2020 (Chinese)
  • 专题文章：COVID-19、抗微生物药物耐药性和
    流行病
  • 案例分析：以雌犬Goldensparkles为例学习兽医抗微生物
    药物敏感性试验
  • 实用提示：近平滑念珠菌复合群药敏解释的应用
  • 热门话题：头孢地尔和来法莫林：临床微生物学家需要知道
    什么？
  • 悼念: Mary Jane Ferraro, PhD, MPH

• Volume 5, Issue 2 - July 2020 (English)
  • Feature Article: COVID-19 and Antimicrobial Resistance (AMR) and Pandemics
  • Case Study: Learning about Veterinary AST from Lady Glittersparkles!
  • Practical Tips: Applying Susceptibility Interpretations to the Candida parapsilosis Species Complex
  • Hot Topic: Cefiderocol and Lefamulin: What Do Clinical Microbiologists Need to Know?
  • In Memoriam: Mary Jane Ferraro, PhD, MPH

• Volume 5, Issue 1 - January 2020 (English)
  • New Information for M100
  • Future CLSI Meetings
  • Featured Article: Ensuring Reliable Antimicrobial Susceptibility Test (AST) Results When Using an Automated AST System
  • Case Study: The Importance of Being Specific: Staphylococcus Species-Specific Breakpoints for Methicillin (Oxacillin) Resistance
  • Practical Tips: A Short Lesson in Fungal Taxonomy: What is CLSI’s Stance?
  • Hot Topic: Oh No, Enterobacterales?? More Nomenclature Changes

• Volume 4, Issue 2 - June 2019 (Chinese)
  • CLSI未来的会议
  • 新的和升级的文件
  • M100的新信息
  • 特色文章: 对检测新抗微生物药物的要求进行评估的实践 方法
  • 实用小贴士: 我们在哪里可以找到耳念珠菌的最新资源？
  • 热门话题: 抗生素耐药性实验室网络(AR Lab Network) ——通过提供扩展的抗微生物药物敏感性检测 来弥合差距
  • 纪念: Sydney M. Finegold，医学博士

• Volume 4, Issue 2 - June 2019 (English)
  • Future CLSI Meetings
  • New/Updated Documents
  • New Information on M100
  • Featured Article: Practical Approach to Evaluating Requests to Test New Antimicrobials
  • Practical Tips: Where Can We Find the Latest Resources for Candida auris?
  • Hot Topic: The Antibiotic Resistance Laboratory Network (AR Lab Network) – Bridging the Gap by Offering Expanded Antimicrobial Susceptibility Testing
  • In Memoriam: Sydney M. Finegold, MD

• Volume 4, Issue 1 - January 2019 (Chinese)
  • 专题文章： 应用氟喹诺酮类药物的药代动力学、药效学和 更新的革兰阴性菌临床折点来确定最佳剂量
  • 病例研究： 深入了解肠杆菌科头孢唑林的报告
  • 实用技巧： #1 对分离自临床标本的念珠菌，何时应该做 抗真菌药物敏感性试验？
  • 实用技巧：#2 CLSI和EUCAST推荐的纸片扩散法中（药物） 纸片含量的差异
  • 热点： 头孢唑啉对MSSA的接种效应
  • 质量角： 临床研究中的β 内酰胺类/β 内酰胺酶抑制剂 复合制剂的抗微生物药物敏感试验的质量控 制

• Volume 4, Issue 1 - January 2019 (English)
  • Featured Article: Applying Fluoroquinolone Pharmacokinetics, Pharmacodynamics, and Updated Clinical Breakpoints for Gram-Negative Pathogens to Determine Optimal Dosing
  • Case Study: Digging Deeper into Understanding Cefazolin Reporting for Enterobacteriaceae
  • Practical Tips: #1 When Should Antifungal Susceptibility Testing be Performed for Candida species Isolated from Clinical Specimens?
  • Practical Tips: #2 Differences in Disk Content Recommended by CLSI and EUCAST for Disk Diffusion Testing
  • Hot Topic: The Cefazolin Inoculum Effect for MSSA
  • Quality Corner: Antimicrobial Susceptibility Testing Quality Control of β-lactam/β-lactamase Inhibitor Combination Agents in Clinical Development

• Volume 3, Issue 2 Spring 2018 (English)
  • Featured Article: Part 1 New β-lactam combination agents for the treatment of Gram-negative bacterial infections: what the clinical microbiologist needs to know!
  • Featured Article: Part 2 Why all the fuss over quality control of β-lactam combination agents?
  • Case Study: Cefazolin, Urine, and Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis: Entertaining Solutions for Antimicrobial Susceptibility Testing and Reporting
  • Burning Question: What Should Clinical Laboratorians Know About Gonorrhea in 2018?
  • Hot Topic: It’s Enough to mec You Crazy!

• Volume 3, Issue 1 Winter 2018 (Chinese)
  • 21世纪治愈法案（The 21st Century Cures Act）——令人振奋的新闻
  • 专题文章：理解药代动力学(PK)和药效学 (PD)
  • 病例研究：血培养阳性样本直接检测 MRSA/MSSA
  • 最关注的问题：临床实验室应该何时进行 碳青霉烯酶检测试验？
  • 呼吸系统疾病和抗生素管理的需求
  • 社区获得性肺炎相关细菌的抗微生物药物 敏感试验
  • 热点话题——耳念珠菌

• Volume 3, Issue 1 Winter 2018 (English)
  • 21st Century Cures Act: Exciting News
  • Feature Article: Understanding Pharmacokinetics (PK) and Pharmacodynamics (PD)
  • Case Study: Direct Detection of MRSA/MSSA from Positive Blood Cultures
  • Burning Question: When Should Clinical Microbiology Laboratories Perform Carbapenemase Detection Tests
  • Article: Respiratory Illnesses and the Need for Antibiotic Stewardship
  • Article: Antimicrobial Susceptibility Testing of Bacteria Associated with Community-Acquired Pneumonia
  • Hot Topic: Candida auris

• Boletín de AST noticias de Junio 2017 (Español)
  Translation by German Esparza, MSc, Director of Clinical Micro Proficiency Testing Proasecal, Proasecal LTD 
  • La iniciativa One Health
  • ¿Que es la Antibiotic Resistance Laboratory Network (ARLN)?
  • Un nuevo test fenotípico para la detección de Carbapenemasas - The Modified Carbapenem Inactivation Method (mCIM)
  • Carbapenems y Enterobacteriaceae: Cual es la diferencia entre CRE vs productores de carbapanemasa (CP)- ¿CRE vs no-CP-CRE?
  • Nuevos desarrollos en pruebas de susceptibilidad antifúngica – Puntos de corte específicos para especies de Candida spp.
  • 10 El acta de curas para el sigo 21 y el futuro de AST
  • Tema Candente – Carbapenemasas OXA
  • En memoria – Dr. Paul Schreckenberger

• Volume 2, Issue 1 Spring 2017 (English)
  • The One Health Initiative
  • What is the Antibiotic Resistance Laboratory Network (ARLN)
  • A New Phenotypic Test for Detection of Carbapenemases – The Modified Carbapenem Inactivation Method (mCIM)
  • Carbapenems and Enterobacteriaceae: What is the difference between CRE vs Carbapenemase-Producing (CP)-CRE vs nonCP-CRE?
  • Newer Developments in Antifungal Susceptibility Testing - Species-Specific Breakpoints for Candida spp.
  • The 21st Century Cures Act and the Future of AST
  • Hot Topic – OXA Carbapenemases
  • In Memoriam – Dr. Paul Schreckenberger

• Volume 1, Issue 2 Winter 2016
  • Do You Need Help With Verification of Your AST System?
  • Special Considerations for Susceptibility Testing of Streptococcus agalactiae (Group B Streptococcus)
  • Continuing Conversation About Colistin!
  • The CLSI Anaerobe Working Group and Anaerobe Susceptibility Testing
  • Resistance Hot Topic! Vancomycin-Variable Enterococci:
    An Unrecognized Threat?

• Volume 1, Issue 1 Spring 2016
  • About CLSI AST ORWG
  • CLSI AST Subcommittee and Meetings
  • Availability of CLSI AST Subcommittee Materials
  • Recently Published CLSI AST Documents
  • Educational Materials for Carbapenem-resistant Enterobacteriaceae (CRE)